Status and phase
Conditions
Treatments
About
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.
The study will consist of 3 periods:
Period 1: eligible participants will be randomized 1:1 to IMVT-1402 or placebo SC QW for 12 weeks.
Period 2: participants who completed Period 1 will receive IMVT-1402 SC QW for 14 weeks.
Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 SC QW for 26 weeks.
Full description
The total study duration per participant is up to 67 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
56 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Central Study Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal